--News Direct--
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that its subsidiary Evolutionary Biologics, Inc. (“EvoBio”), a developer, manufacturer and distributor of private label regenerative medicine products and branded state-of-the-art biologic products, created in a pharmaceutical grade laboratory and manufacturing facility has executed a Product Manufacturing Agreement with a distributor of medical devices that desires to market a MSC Exosome product from EvoBio as a private label on an exclusive basis. The Company believes the new relationship will generate at least $2 million in new revenue.
Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Our expansion of Evolutionary Biologics has continued beyond our original strategy. As I mentioned earlier this year, we have created a relationship with a state-of-the-art laboratory which has enabled us to not only manufacture the highest quality products for ourselves, but to manufacture world class products for strategic partners that can be marketed as “private label.” This new initiative comes as we continue to prepare the company for major growth and expansion.”
On Tuesday of this week, Emergent announced the engagement of BF Borgers CPA PC, a full-service audit, tax, accounting, and advisory firm, as its Public Company Accounting Oversight Board (“PCAOB”) qualified auditor to audit the Company’s PharmaZu subsidiary’s financial statement for the two-year period ending December 31, 2022 according to Generally Accepted Accounting Principles (“GAAP”). GAAP is the accounting standard adopted by the Securities and Exchange Commission (“SEC”) and is the default accounting standard used by companies based in the United States. For further information, please see Press Release dated May 9th, 2023.
On Thursday of last week, Emergent announced the engagement of Boustead Securities LLC. to act as exclusive financial advisor with respect to a planned corporate financing transaction including the private placement of securities (“pre-IPO Financing”) and a planned $10 million initial public offering of Emergent;s subsidiary, PharmaZu and its common stock (“IPO”) that will apply for listing on NASDAQ with NO DILUTION to the Emergent Shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness, using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on NASDAQ, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Subsequently, Emergent plans to distribute the shares of PharmaZu as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. For further information, please see Press Release dated May 4th, 2023.
ABOUT EMERGENT HEALTH CORPORATION
Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter.
Before using any products, you should always consult with your Veterinarian and/or Family Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
FOR MORE INFORMATION, PLEASE CONTACT:
Jim Morrison, CEO
Emergent Health Corporation Website
info@emergenthealthcompany.com
Contact Details
Emergent Health Corp.
info@emergenthealthcompany.com
Company Website
https://emergenthealthcompany.com/
View source version on newsdirect.com: https://newsdirect.com/news/emergent-health-subsidiary-evolutionary-biologics-executes-product-manufacturing-agreement-with-major-player-in-the-regenerative-medicine-space-348446874
